News Center

News Center

Talent drives enterprise to achieve outstanding results—Shengshi Taikoo's two key personnel clinch new honors at the 3rd Jinji Lake Skills Invitational Competition

Release date:

2022-02-22

As Suzhou continues its ongoing battle against the pandemic, it has once again highlighted how critical strong analytical technicians are to the pharmaceutical industry. Recently, there was exciting news from the 11th High-Skill Competition and the 3rd Jinji Lake Skills Invitational: two key technical experts from Shengshi Taikang’s New Drug R&D – Analytical Department advanced steadily through the rounds, ultimately earning a well-deserved second-place award in the final team competition of the Biochemical Pharmaceutical Engineering Technology (Employee Group) category.

1

The 11th High-Skill Competition and the 3rd Jinji Lake Skills Invitational Tournament 2021 kicked off with the theme "Mastering Craftsmanship, Empowering the Future," featuring 22 competitive events. The competition closely aligns with the skill talent demands driven by the park's key industries and emerging sectors. Since its launch, it has attracted over 6,600 participants, with 2,927 ultimately advancing to the finals.

1

A high-quality talent pool is an essential factor for corporate innovation. Two key employees from the Analytical Department of Shengshi Taikang’s New Drug R&D team participated in the 3rd Jinji Lake Skills Invitational—the "Baituo & Agilent Cup" National Open Challenge Competition in Biopharmaceutical Chromatography Analysis Technology. After intense competition in both the preliminary and final rounds, they ultimately secured the second-place prize in the group competition of the Biochemical Pharmaceutical Engineering Technology category (for employee teams) during the finals.

1

Founded in 2010 in Suzhou Industrial Park, Shengshi Taikе is a biotechnology company dedicated to the research and development of small-molecule drugs in the areas of blood sugar control, cancer therapy, and rare diseases.
 
Since its establishment, the company has built a robust pipeline of Class 1 innovative drugs. Among them, its independently developed drug, phosphate sengliflozin—a novel DPP-4 inhibitor—is currently in Phase 3 clinical trials. All trial participants are expected to complete the study by mid-2022. Preliminary results from these completed trials indicate that phosphate sengliflozin demonstrates excellent safety profiles and effectively reduces glycated hemoglobin levels. If the drug successfully meets its primary clinical efficacy endpoints, its approval will fill a significant gap in China's domestic production of DPP-4 inhibitors—currently, all approved products are imported registrations—thus opening up vast market opportunities ahead.
 
Just recently, Shengshi Taikang's generic drug Teriflunomide Tablets officially received approval in China, with the approved indication being relapsing multiple sclerosis. This marks the first domestically produced Teriflunomide to be approved for market launch in China. Once available, it will provide domestic patients with a high-quality, more accessible treatment option.

 

 

Prev：

Shengshi Taikang Named to the "2021 Most Influential Companies in Healthcare" List

Next：

Great news! Dr. Wang Tong, CSO of Shengshi Taikang, and Dr. Zhao Jiahong, CMO, have been named Gusu Leading Talents.

中企跨境-全域组件 制作前进入CSS配置样式

在线客服添加返回顶部

页面顺滑的滚动

屏蔽页面上图片的alt/title提示

右侧在线客服样式 1,2,3 2

图片alt标题设置： Fland Environmental

表单验证提示文本： The content cannot be empty!

循环体没有内容时： Content is being organized—please wait!

CSS / JS 文件放置地